Introduction: Paget's disease of bone (PDB) is a chronic disorder of bone turnover, characterized by increased osteoclast-mediated bone resorption and subsequent compensatory increase in new bone formation, resulting in a disorganized mosaic of woven and lamellar bone at the affected skeletal sites. As a result, bone pain, osteoarthritis, noticeable deformities, nerve compression syndromes, fractures and, less frequently, neoplastic degeneration can occur. Areas covered: The published literature has been critically appraised, focusing on three main areas: epidemiology, pathogenesis (particularly regarding SQSTM1 mutations and other genetic aspects) and treatment of PDB. Expert opinion: Over the last two decades, there have been major advances in our understanding of pathogenesis and management of PDB. Mutations in SQSTM1 gene (encoding p62) have been identified in a consistent proportion of familial cases and treatment opportunities have been recently improved with the use of intravenous aminobisphosphonate regimens, allowing long-term remission of the disease. However, further research is needed to explore: i) the molecular mechanisms leading to PDB in SQSTM1 mutation carriers; ii) the genetic cause of the disease in SQSTM1-negative patients; and iii) to identify in more detail the environmental triggers and the mechanisms by which they interact with genetic background to influence susceptibility to the disease.
|Titolo:||Paget's disease of bone: epidemiology, pathogenesis and pharmacotherapy|
|Citazione:||Gennari, L., Merlotti, D., Rendina, D., Gianfrancesco, F., Esposito, T., & Nuti, R. (2014). Paget's disease of bone: epidemiology, pathogenesis and pharmacotherapy. EXPERT OPINION ON ORPHAN DRUGS, 2, 591-603.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: